专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008073450A2 BENZAMIDE COMPOUNDS 审中-公开
标题翻译：苯酰胺化合物
公开(公告)号：WO2008073450A2
公开(公告)日：2008-06-19
申请号：PCT/US2007025390
申请日：2007-12-12
申请人： UNIV GEORGETOWN , SAMARITAN PHARMACEUTICALS INC , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
IPC分类号： A61K31/497
CPC分类号： A61K31/497 , C07D209/20
摘要： The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof, wherein the pathogen is Avian Influenza, Avian Influenza A, Influenza A, Influenza B, hepatitis B virus, or hepatitis C virus. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了用于预防或治疗哺乳动物例如人的病理状态或症状的治疗方法，其中涉及病原体对哺乳动物细胞的感染性并且需要抑制其感染性，包括对需要这种疗法是有效量的抑制病原性感染性的氨基酸哌嗪酰胺的N-苯甲酰胺衍生物，包括其药学上可接受的盐，其中病原体是禽流感，甲型禽流感，甲型流感，甲型流感，乙型肝炎 B病毒或丙型肝炎病毒。本发明还提供了用于预防或治疗哺乳动物（例如人）的神经病理状况或症状的治疗方法，其包括向需要这种治疗的哺乳动物施用有效量的本发明的哌嗪基酰胺的N-苯甲酰胺衍生物其氨基酸，包括其药学上可接受的盐。

2. 发明申请

WO2005112922A2 BENZAMIDE COMPOUNDS 审中-公开
标题翻译：苯甲酸化合物
公开(公告)号：WO2005112922A2
公开(公告)日：2005-12-01
申请号：PCT/US2005014131
申请日：2005-04-22
申请人： SAMARITAN PHARMACEUTICALS , UNIV GEORGETOWN , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
IPC分类号： A61K31/416
CPC分类号： A61K31/416
摘要： The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了预防或治疗哺乳动物（例如人）中的病理状况或症状的治疗方法，其中牵涉到病原体如逆转录病毒对哺乳动物细胞的感染性，并且希望抑制其感染性，包括给予需要这种治疗的哺乳动物，有效量的抑制病原性感染性的氨基酸的哌嗪基酰胺的N-苯甲酰胺衍生物，包括其药学上可接受的盐。本发明还提供了用于预防或治疗哺乳动物（例如人）的神经病理学病症或症状的治疗方法，其包括对需要这种治疗的哺乳动物施用有效量的哌嗪基酰胺的N-苯甲酰胺衍生物其氨基酸，包括其药学上可接受的盐。

3. 发明申请

WO2005112922A9 BENZAMIDE COMPOUNDS 审中-公开
标题翻译：苯甲酸化合物
公开(公告)号：WO2005112922A9
公开(公告)日：2006-03-09
申请号：PCT/US2005014131
申请日：2005-04-22
申请人： SAMARITAN PHARMACEUTICALS , UNIV GEORGETOWN , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS , XU JING
IPC分类号： A61K31/416
CPC分类号： A61K31/416
摘要： The invention provides a therapeutic method for preventing or treating a pathological condition or symptom in a mammal, such as a human, wherein the infectivity of a pathogen such as a retrovirus toward mammalian cells is implicated and inhibition of its infectivity is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof that inhibits pathogenic infectivity, including pharmaceutically acceptable salts thereof. The invention also provides a therapeutic method for preventing or treating a neuropathological condition or symptom in a mammal, such as human, comprising administering to a mammal in need of such therapy, an effective amount of an N-benzamide derivative of a piperazinyl amide of an amino acid thereof, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供了预防或治疗哺乳动物（例如人）中的病理状况或症状的治疗方法，其中牵涉到病原体如逆转录病毒对哺乳动物细胞的感染性，并且希望抑制其感染性，包括给予需要这种治疗的哺乳动物，有效量的抑制病原性感染性的氨基酸的哌嗪基酰胺的N-苯甲酰胺衍生物，包括其药学上可接受的盐。本发明还提供了用于预防或治疗哺乳动物（例如人）的神经病理学病症或症状的治疗方法，其包括对需要这种治疗的哺乳动物施用有效量的哌嗪基酰胺的N-苯甲酰胺衍生物其氨基酸，包括其药学上可接受的盐。

4. 发明申请

WO2006107902A2 USE OF SPIROSTENOLS TO TREAT MITOCHONDRIAL DISORDERS 审中-公开
标题翻译：使用螺旋体治疗麻醉病
公开(公告)号：WO2006107902A2
公开(公告)日：2006-10-12
申请号：PCT/US2006012380
申请日：2006-03-31
申请人： SAMARITAN PHARMACEUTICALS INC , UNIV GEORGETOWN , LECANU LAURENT , TILLEMENT LAURENT , PAPADOPOULOS VASSILIOS , YAO WENGUO , GREESON JANET
发明人： LECANU LAURENT , TILLEMENT LAURENT , PAPADOPOULOS VASSILIOS , YAO WENGUO , GREESON JANET
IPC分类号： A61K31/58 , A61P3/10 , A61P9/00 , A61P9/10 , A61P21/00 , A61P27/00
CPC分类号： A61K31/58
摘要： The present invention relates to methods and compositions for treating, preventing or reducing the risk of developing a mitochondrial disorder or disease or the symptoms associated with a mitochondrial disorder or disease.
摘要翻译：本发明涉及用于治疗，预防或降低发展线粒体疾病或疾病或与线粒体疾病或疾病相关的症状的风险的方法和组合物。

5. 发明申请

WO2006107902A9 USE OF SPIROSTENOLS TO TREAT MITOCHONDRIAL DISORDERS 审中-公开
标题翻译：使用螺旋体治疗麻醉病
公开(公告)号：WO2006107902A9
公开(公告)日：2007-01-18
申请号：PCT/US2006012380
申请日：2006-03-31
申请人： SAMARITAN PHARMACEUTICALS INC , UNIV GEORGETOWN , LECANU LAURENT , TILLEMENT LAURENT , PAPADOPOULOS VASSILIOS , YAO WENGUO , GREESON JANET
发明人： LECANU LAURENT , TILLEMENT LAURENT , PAPADOPOULOS VASSILIOS , YAO WENGUO , GREESON JANET
IPC分类号： A61K31/58 , A61P3/10 , A61P9/00 , A61P9/10 , A61P21/00 , A61P27/00
CPC分类号： A61K31/58
摘要： The present invention relates to methods and compositions for treating, preventing or reducing the risk of developing a mitochondrial disorder or disease or the symptoms associated with a mitochondrial disorder or disease.
摘要翻译：本发明涉及用于治疗，预防或降低发展线粒体疾病或疾病或与线粒体疾病或疾病相关的症状的风险的方法和组合物。

6. 发明申请

WO2004080416A3 ANIMAL MODEL SIMULATING NEUROLOGIC DISEASE 审中-公开
标题翻译：动物模型模拟神经疾病
公开(公告)号：WO2004080416A3
公开(公告)日：2004-12-23
申请号：PCT/US2004007457
申请日：2004-03-11
申请人： SAMARITAN PHARMACEUTICALS INC , UNIV GEORGETOWN , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS
IPC分类号： A01K67/00 , A01K67/027 , A61K20060101 , A61K38/00 , A61K49/00 , G01N33/00
CPC分类号： A01K67/027 , A01K2227/105 , A01K2267/0312 , A61K49/0008
摘要： The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe , Abeta42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.
摘要翻译：本发明涉及药理学非人动物模型的发展，其将记忆丧失与在患有阿尔茨海默病的受试者的脑中发现的组织病理学特征相关联。在一个实施方案中，在年轻成人Long-Evans大鼠的左心室中四个星期连续输注Fe 2+，Abeta42和丁硫氨酸砜亚胺（FAB）溶液诱导伴随脑脊液中过度磷酸化Tau蛋白水平增加的记忆障碍。来自治疗动物的大脑在海马和皮质中显示神经炎斑块，缠结，神经元丢失，星形胶质细胞增生和小神经胶质细胞增生症。本发明可用于评估神经疾病的预防，治疗和诊断手段。

7. 发明申请

WO2007092458A8 ANTIDOTES TO EXOGENOUS NEUROTOXIC AGENTS 审中-公开
标题翻译：抗异常神经毒素抗体
公开(公告)号：WO2007092458A8
公开(公告)日：2007-09-27
申请号：PCT/US2007003170
申请日：2007-02-05
申请人： SAMARITAN PHARMACEUTICALS INC , UNIV GEORGETOWN , PAPADOPOULOS VASSILIOS , LECANU LAURENT , GREESON JANET
发明人： PAPADOPOULOS VASSILIOS , LECANU LAURENT , GREESON JANET
IPC分类号： A61K31/495 , A61K31/661 , A61K31/662 , A61K45/06 , A61P25/00 , A61P39/02
CPC分类号： A61K31/495 , A61K31/661 , A61K31/662 , A61K45/06 , C07D295/13 , A61K2300/00
摘要： The present application discloses the use of compounds exhibiting both acetylcholinesterase (AchE) inhibition properties and s-1 receptor agonist capacities for treating a mammal exposed to an exogenous neurotoxic agent, in particular nerve gas.
摘要翻译：本申请公开了使用表现出乙酰胆碱酯酶（AchE）抑制特性和s-1受体激动剂能力的化合物来治疗暴露于外源性神经毒性剂，特别是神经气体的哺乳动物。

8. 发明申请

WO2007103162A2 STRUCTURE BASED DRUG DESIGN OF STEROIDOGENESIS INHIBITORS 审中-公开
标题翻译： STEROIDOGENESIS抑制剂的基于结构的药物设计
公开(公告)号：WO2007103162A2
公开(公告)日：2007-09-13
申请号：PCT/US2007005325
申请日：2007-03-01
申请人： SAMARITAN PHARMACEUTICALS INC , UNIV GEORGETOWN , PAPADOPOULOS VASSILIOS , AKULA NAGARAJU , GREESON JANET , LECANU LAURENT
发明人： PAPADOPOULOS VASSILIOS , AKULA NAGARAJU , GREESON JANET , LECANU LAURENT
IPC分类号： A61K31/57
CPC分类号： A61K31/57
摘要： Steroidogenesis begins with the transfer of free cholesterol from intracellular stores into mitochondria. The peripheral-type benzodiazepine receptor (PBR) and steroidogenic acute regulatory protein (StAR) function in this process, functioning together to shuttle cholesterol from outside the mitochondria to the inner mitochondrial membrane. The present invention provides methods of using structure-based drug design to identify peptide and substituted steroid compounds that can inhibit the activity of PBR and StAR via interaction with their cholesterol-binding domains. These approaches facilitated the identification of a number of inhibitory ligands that decrease steroid biosynthesis.
摘要翻译：类固醇生成开始于游离胆固醇从细胞内储存转移到线粒体中。外周型苯二氮类受体（PBR）和类固醇激素急性调节蛋白（StAR）在这一过程中起作用，共同作用，将胆固醇从线粒体外部转移到内线粒体膜。本发明提供了使用基于结构的药物设计来鉴定通过与其胆固醇结合结构域相互作用可抑制PBR和StAR的活性的肽和取代的类固醇化合物的方法。这些方法有助于鉴定减少类固醇生物合成的许多抑制性配体。

9. 发明申请

WO2006044665A3 NEUROPROTECTIVE SPIROSTENOL PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：神经保护性螺旋体药物组合物
公开(公告)号：WO2006044665A3
公开(公告)日：2007-07-05
申请号：PCT/US2005037023
申请日：2005-10-14
申请人： UNIV GEORGETOWN , SAMARITAN PHARMACEUTICALS INC , YAO ZHI-XING , LECANU LAURENT , TEPER GARY , GREESON JANET , PAPADOPOULOS VASSILIOS
发明人： YAO ZHI-XING , LECANU LAURENT , TEPER GARY , GREESON JANET , PAPADOPOULOS VASSILIOS
IPC分类号： A01N45/00 , A61K31/56 , A61K31/58 , A61K31/585 , A61K31/59
CPC分类号： A61K31/58 , A61K31/56 , A61K31/585 , A61K31/59
摘要： The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with a neurodegenerative disorder such as neurotoxicity or a neuropathology in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The invention further provides a method for inducing stem cell differentiation into neuronal cells, by administering to the patient a therapeutically effective amount of a compound of the invention.
摘要翻译：本发明涉及用于治疗，预防或降低发生与神经变性疾病相关的病症或疾病或与神经变性疾病如神经毒性或神经病理学相关的症状的风险的方法，试剂盒，组合和组合物，特别是 β-淀粉样蛋白诱导的神经毒性和阿尔茨海默病。本发明还提供了通过向患者施用治疗有效量的本发明化合物来诱导干细胞分化成神经细胞的方法。

10. 发明申请

WO2004108666A3 NEUROPROTECTIVE BENZOATE AND BENZAMIDE COMPOUNDS 审中-公开
标题翻译：神经保护性苯甲酸和苯甲酸酯化合物
公开(公告)号：WO2004108666A3
公开(公告)日：2005-03-31
申请号：PCT/US2004016036
申请日：2004-05-20
申请人： SAMARITAN PHARMACEUTICALS , UNIV GEORGETOWN , LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS
发明人： LECANU LAURENT , GREESON JANET , PAPADOPOULOS VASSILIOS
IPC分类号： A61K31/135 , C07D20060101
CPC分类号： A61K31/135 , A61K31/16 , A61K31/165
摘要： The invention provides a therapeutic method for treating at least one symptom of a neurological disorder or disease such as Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of beta amyloid peptide and/or glutamate in mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of an N-arylamide or an (N-aminoalkyl)benzamide, including pharmaceutically acceptable salts thereof.
摘要翻译：本发明提供在哺乳动物（例如人）中治疗至少一种神经障碍或疾病如阿尔茨海默病的症状的治疗方法，其中涉及哺乳动物细胞中β淀粉样肽和/或谷氨酸的病原体的毒性并且期望抑制随后诱导的病理学途径，包括向需要这种治疗的哺乳动物施用有效量的N-芳基酰胺或（N-氨基烷基）苯甲酰胺，包括其药学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式